Peter Hunt, MD

Headshot of Peter Hunt
User Profile Photo

Peter Hunt, MD

User Profile Name
Co-Director, UCSF-Bay Area CFAR
Professor, School of Medicine
User Profile Title
User Profile Email

Biography

Peter Hunt is a Professor of Medicine in the Division of Experimental Medicine (DEM) at the University of California San Francisco. He also serves as Associate Chief for Research for the ZSFG-UCSF Department of Medicine, Co-Director of the UCSF-GIVI Center for AIDS Research (for basic and translational science), and as a member of the Leadership Committee of the UCSF AIDS Research Institute. He also recently completed terms as Interim Chief of the DEM and Chair of the ACTG Inflammation and End Organ Disease Transformative Science Group. His primary research focus is on the inflammatory consequences of HIV infection. His clinic-based translational research program seeks to understand the determinants of persistent immune activation both in the presence and the absence of antiretroviral therapy, and to assess the impact of immune activation on clinical outcomes. He collaborates extensively with a multi-disciplinary team of investigators to assess the impact of persistent immune activation despite viral suppression on mortality and chronic diseases associated with aging (i.e., cardiovascular disease) and conducts clinical trials of novel immune-based interventions designed to decrease immune activation. Dr. Hunt has also led a translational research program in Mbarara, Uganda, focused on the determinants of immune recovery during suppressive antiretroviral therapy in that setting. He also helped develop a large mucosal immunology program at Zuckerberg San Francisco General Hospital focused on the impact of HIV on gut-associated lymphoid tissue and the determinants of microbial translocation in HIV infection. In 2016, he started a laboratory in the DEM, focused on the immunologic consequences of asymptomatic CMV replication during treated HIV infection as well as the adaptive immune defects that persist in this setting in an effort to develop targets for interventions to reduce morbidity and mortality.

User Profile Bio

Displaying 126 - 150 of 318

  1. Rutishauser RL, Hartogensis W, Deguit CD, Krone M, Hoh R, Hecht FM, Pilcher CD, Bacchetti P, Deeks SG, Hunt PW, McCune JM. Early and Delayed Antiretroviral Therapy Results in Comparable Reductions in CD8+ T Cell Exhaustion Marker Expression. AIDS Res Hum Retroviruses. 2017 07; 33(7):658-667.
  2. Ribeiro SP, Milush JM, Cunha-Neto E, Kallas EG, Kalil J, Passero LFD, Hunt PW, Deeks SG, Nixon DF, SenGupta D. Correction: p16INK4a Expression and Immunologic Aging in Chronic HIV Infection. PLoS One. 2017; 12(4):e0176509.
  3. Chang JL, Lee SA, Tsai AC, Musinguzi N, Muzoora C, Bwana B, Boum Y, Haberer JE, Hunt PW, Martin J, Bangsberg DR, Kroetz DL, Siedner MJ. CYP2B6 Genetic Polymorphisms, Depression, and Viral Suppression in Adults Living with HIV Initiating Efavirenz-Containing Antiretroviral Therapy Regimens in Uganda: Pooled Analysis of Two Prospective Studies. AIDS Res Hum Retroviruses. 2018 11; 34(11):982-992.
  4. Doitsh G, Galloway NL, Geng X, Yang Z, Monroe KM, Zepeda O, Hunt PW, Hatano H, Sowinski S, Muñoz-Arias I, Greene WC. Corrigendum: Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature. 2017 04 06; 544(7648):124.
  5. Khoury G, Fromentin R, Solomon A, Hartogensis W, Killian M, Hoh R, Somsouk M, Hunt PW, Girling V, Sinclair E, Bacchetti P, Anderson JL, Hecht FM, Deeks SG, Cameron PU, Chomont N, Lewin SR. Human Immunodeficiency Virus Persistence and T-Cell Activation in Blood, Rectal, and Lymph Node Tissue in Human Immunodeficiency Virus-Infected Individuals Receiving Suppressive Antiretroviral Therapy. J Infect Dis. 2017 03 15; 215(6):911-919.
  6. Crane HM, Paramsothy P, Drozd DR, Nance RM, Delaney JA, Heckbert SR, Budoff MJ, Burkholder GA, Willig JH, Mugavero MJ, Mathews WC, Crane PK, Moore RD, Eron JJ, Napravnik S, Hunt PW, Geng E, Hsue P, Rodriguez C, Peter I, Barnes GS, McReynolds J, Lober WB, Crothers K, Feinstein MJ, Grunfeld C, Saag MS, Kitahata MM. Types of Myocardial Infarction Among Human Immunodeficiency Virus-Infected Individuals in the United States. JAMA Cardiol. 2017 Mar 01; 2(3):260-267.
  7. Maidji E, Somsouk M, Rivera JM, Hunt PW, Stoddart CA. Replication of CMV in the gut of HIV-infected individuals and epithelial barrier dysfunction. PLoS Pathog. 2017 02; 13(2):e1006202.
  8. O'Brien MP, Hunt PW, Kitch DW, Klingman K, Stein JH, Funderburg NT, Berger JS, Tebas P, Clagett B, Moisi D, Utay NS, Aweeka F, Aberg JA. A Randomized Placebo Controlled Trial of Aspirin Effects on Immune Activation in Chronically Human Immunodeficiency Virus-Infected Adults on Virologically Suppressive Antiretroviral Therapy. Open Forum Infect Dis. 2017; 4(1):ofw278.
  9. Haberer JE, Musinguzi N, Tsai AC, Boum Y, Bwana BM, Muzoora C, Hunt PW, Martin JN, Bangsberg DR. Real-time electronic adherence monitoring plus follow-up improves adherence compared with standard electronic adherence monitoring. AIDS. 2017 01 02; 31(1):169-171.
  10. Avelino-Silva VI, Miyaji KT, Hunt PW, Huang Y, Simoes M, Lima SB, Freire MS, Caiaffa-Filho HH, Hong MA, Costa DA, Dias JZ, Cerqueira NB, Nishiya AS, Sabino EC, Sartori AM, Kallas EG. CD4/CD8 Ratio and KT Ratio Predict Yellow Fever Vaccine Immunogenicity in HIV-Infected Patients. PLoS Negl Trop Dis. 2016 12; 10(12):e0005219.
  11. Okello S, Asiimwe SB, Kanyesigye M, Muyindike WR, Boum Y, Mwebesa BB, Haberer JE, Huang Y, Williams K, Burdo TH, Tracy RP, Bangsberg DR, Mocello AR, Martin JN, Hunt PW, Siedner MJ. D-Dimer Levels and Traditional Risk Factors Are Associated With Incident Hypertension Among HIV-Infected Individuals Initiating Antiretroviral Therapy in Uganda. . 2016 Dec 01; 73(4):396-402.
  12. Hodes RJ, Sierra F, Austad SN, Epel E, Neigh GN, Erlandson KM, Schafer MJ, LeBrasseur NK, Wiley C, Campisi J, Sehl ME, Scalia R, Eguchi S, Kasinath BS, Halter JB, Cohen HJ, Demark-Wahnefried W, Ahles TA, Barzilai N, Hurria A, Hunt PW. Disease drivers of aging. Ann N Y Acad Sci. 2016 12; 1386(1):45-68.
  13. Ribeiro SP, Milush JM, Cunha-Neto E, Kallas EG, Kalil J, Passero LFD, Hunt PW, Deeks SG, Nixon DF, SenGupta D. p16INK4a Expression and Immunologic Aging in Chronic HIV Infection. PLoS One. 2016; 11(11):e0166759.
  14. Kiniry BE, Ganesh A, Critchfield JW, Hunt PW, Hecht FM, Somsouk M, Deeks SG, Shacklett BL. Predominance of weakly cytotoxic, T-betLowEomesNeg CD8+ T-cells in human gastrointestinal mucosa: implications for HIV infection. Mucosal Immunol. 2017 07; 10(4):1008-1020.
  15. Hunt PW. Very Early ART and Persistent Inflammation in Treated HIV. Clin Infect Dis. 2017 01 15; 64(2):132-133.
  16. Nedellec R, Herbeck JT, Hunt PW, Deeks SG, Mullins JI, Anton ED, Reeves JD, Mosier DE. High-Sequence Diversity and Rapid Virus Turnover Contribute to Higher Rates of Coreceptor Switching in Treatment-Experienced Subjects with HIV-1 Viremia. AIDS Res Hum Retroviruses. 2017 03; 33(3):234-245.
  17. Hunt PW, Lee SA, Siedner MJ. Immunologic Biomarkers, Morbidity, and Mortality in Treated HIV Infection. J Infect Dis. 2016 Oct 01; 214 Suppl 2:S44-50.
  18. Bebell LM, Siedner MJ, Musinguzi N, Boum Y, Bwana BM, Muyindike W, Hunt PW, Martin JN, Bangsberg DR. Trends in one-year cumulative incidence of death between 2005 and 2013 among patients initiating antiretroviral therapy in Uganda. Int J STD AIDS. 2017 07; 28(8):800-807.
  19. Feinstein MJ, Kim JH, Bibangambah P, Sentongo R, Martin JN, Tsai AC, Bangsberg DR, Hemphill L, Triant VA, Boum Y, Hunt PW, Okello S, Siedner MJ. Ideal Cardiovascular Health and Carotid Atherosclerosis in a Mixed Cohort of HIV-Infected and Uninfected Ugandans. AIDS Res Hum Retroviruses. 2017 01; 33(1):49-56.
  20. Conroy AA, Tsai AC, Clark GM, Boum Y, Hatcher AM, Kawuma A, Hunt PW, Martin JN, Bangsberg DR, Weiser SD. Relationship Power and Sexual Violence Among HIV-Positive Women in Rural Uganda. AIDS Behav. 2016 Sep; 20(9):2045-53.
  21. Lee SA, Mefford JA, Huang Y, Witte JS, Martin JN, Haas DW, Mclaren PJ, Mushiroda T, Kubo M, Byakwaga H, Hunt PW, Kroetz DL. Host genetic predictors of the kynurenine pathway of tryptophan catabolism among treated HIV-infected Ugandans. AIDS. 2016 07 17; 30(11):1807-15.
  22. Lee GQ, Lachowski C, Cai E, Lima VD, Boum Y, Muzoora C, Mocello AR, Hunt PW, Martin JN, Bangsberg DR, Harrigan PR. Non-R5-tropic HIV-1 in subtype A1 and D infections were associated with lower pretherapy CD4+ cell count but not with PI/(N)NRTI therapy outcomes in Mbarara, Uganda. AIDS. 2016 07 17; 30(11):1781-8.
  23. Deleage C, Schuetz A, Alvord WG, Johnston L, Hao XP, Morcock DR, Rerknimitr R, Fletcher JL, Puttamaswin S, Phanuphak N, Dewar R, McCune JM, Sereti I, Robb M, Kim JH, Schacker TW, Hunt P, Lifson JD, Ananworanich J, Estes JD. Impact of early cART in the gut during acute HIV infection. JCI Insight. 2016 Jul 07; 1(10).
  24. Hunt PW. Soluble CD163 and Clinical Outcomes in Treated HIV Infection: Insights Into Mechanisms. J Infect Dis. 2016 10 15; 214(8):1132-3.
  25. Younes SA, Freeman ML, Mudd JC, Shive CL, Reynaldi A, Panigrahi S, Estes JD, Deleage C, Lucero C, Anderson J, Schacker TW, Davenport MP, McCune JM, Hunt PW, Lee SA, Serrano-Villar S, Debernardo RL, Jacobson JM, Canaday DH, Sekaly RP, Rodriguez B, Sieg SF, Lederman MM. IL-15 promotes activation and expansion of CD8+ T cells in HIV-1 infection. J Clin Invest. 2016 07 01; 126(7):2745-56.